Return to search

Pillar Biosciences snaps up $29.7m

Boston and Shanghai-based Pillar Biosciences, an NGS clinical cancer diagnostics company, has secured $29.7 million in Series C preferred stock financing.

Boston and Shanghai-based Pillar Biosciences, an NGS clinical cancer diagnostics company, has secured $29.7 million in Series C preferred stock financing. ORI Healthcare Fund led the round.

Source: Press Release